Welcome to our dedicated page for Unity Btech SEC filings (Ticker: UBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unity Btech’s R&D-heavy business means every 8-K trial update, 10-Q cash-flow note, and Form 4 trade can move the stock—yet those disclosures run hundreds of pages of biotech jargon. If you’ve ever tried to pinpoint when a Phase 2 osteoarthritis study reads out or how much runway remains before the next equity raise, you know the challenge.
Stock Titan solves that problem. Our AI reads each Unity Btech quarterly earnings report 10-Q filing, flags fresh clinical milestones, and translates GAAP footnotes into plain English. Real-time alerts surface Unity Btech insider trading Form 4 transactions within minutes of hitting EDGAR, while concise dashboards link directly to the source documents for deeper review. Whether you’re tracking dilution risk through shelf registrations or comparing R&D spend across quarters, the platform keeps every filing type at your fingertips:
- 10-K annual report—cash runway, pipeline prioritization, and Unity Btech annual report 10-K simplified by AI
- 10-Q—quarterly trial costs and burn-rate trends, complete with Unity Btech earnings report filing analysis
- 8-K—material events like trial data releases, partnership terms, or ATM offerings, with Unity Btech 8-K material events explained
- Form 4—executive stock transactions, searchable via Unity Btech Form 4 insider transactions real-time
- DEF 14A proxy—board composition and Unity Btech proxy statement executive compensation
Need help understanding Unity Btech SEC documents with AI? Our summaries highlight which senolytic programs advanced, flag going-concern language, and even calculate cumulative dilution from recent offerings. Spend less time parsing technical filings and more time deciding whether Unity Btech’s senolytic pipeline aligns with your investment thesis.
Deutsche Bank AG is offering $3.0 million of 5.00% Fixed-Rate Callable Senior Debt Funding Notes maturing on 29 June 2029. The notes are issued at 100% of principal (minimum 99.65% for certain institutional or fee-based accounts) in minimum denominations of $1,000. Interest is paid annually in arrears each 30 June, calculated on a 30/360 basis. The bank may, at its sole discretion and subject to regulatory approval, redeem the notes at par in whole (not in part) on any semi-annual Optional Redemption Date beginning 30 June 2026 and ending 30 December 2028.
The securities are unsecured, unsubordinated senior preferred obligations intended to qualify as eligible liabilities for the EU Minimum Requirement for Own Funds and Eligible Liabilities (MREL). They are not FDIC-insured and carry typical Deutsche Bank credit risk. As bail-in eligible instruments, holders explicitly consent to possible Resolution Measures under EU/ German banking law, including write-down to zero or conversion into equity should the Single Resolution Board deem the bank non-viable.
Key economics
- Issue/Settlement dates: 26 June 2025 / 30 June 2025
- Principal amount: $3,000,000
- Gross proceeds to issuer: $2,994,000 after 0.35% maximum selling concession ($3.50 per note)
- CUSIP/ISIN: 25161FJF6 / US25161FJF62
- No stock-exchange listing; book-entry only via DTC
Primary risks include issuer credit risk, discretionary early redemption, interest-rate reinvestment risk if called, and potential bail-in loss under EU resolution rules. The small size and standard terms make the issuance largely immaterial to Deutsche Bank’s capital structure, but investors should assess whether the 5% fixed coupon adequately compensates for the credit and structural risks.
Merus N.V. (MRUS) – Form 144 filing overview
The notice covers a proposed sale of 34,000 common shares that were acquired through a non-qualified stock option exercise on 20 Jun 2025. The seller’s identity is not disclosed in the filing, but the transaction will be executed through RBC Capital Markets LLC on NASDAQ.
Based on the Form 144 data, the aggregate market value of the shares being sold is US $1.79 million. With 69.2 million shares outstanding, the proposed sale represents approximately 0.05 % of the company’s shares, indicating a relatively small, routine disposition. No other sales by the same person were reported in the past three months, and no additional remarks or 10b5-1 plan dates were supplied.
The filing is strictly a notice and does not, by itself, confirm that the sale has occurred. It also states that the seller affirms no undisclosed material adverse information regarding Merus exists at the time of filing.
FAQ
What is the current stock price of Unity Btech (UBX)?
What is the market cap of Unity Btech (UBX)?
What is the core focus of Unity Btech (UBX)?
How do Unity Btech's therapeutics work?
Which disease areas are being targeted by Unity Btech?
What makes Unity Btech's approach to aging therapeutic research unique?
How is Unity Btech positioned within the competitive biopharmaceutical landscape?
What role do clinical trials play in Unity Btech's strategy?
How does Unity Btech ensure scientific and operational transparency?
What should investors know about Unity Btech's market significance without speculating on future performance?
